SHF Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on September 30, 2025. SHF Holdings, Inc. (SHFS), a Delaware corporation, executed a comprehensive capital restructuring to address liquidity needs and regain compliance with Nasdaq listing requirements regarding minimum stockholders' equity.
Key Financial Metrics and Transaction Details
- Capital Raised: The Company entered into a Securities Purchase Agreement with an aggregate purchase price of approximately $28.8 million.
- Cash Proceeds: Net cash proceeds to the Company were approximately $6.1 million. The remainder of the purchase price was satisfied through debt cancellation, asset transfers, and the cancellation of amounts owed to buyers.
- Securities Issued:
- 31,052 shares of Series B Convertible Preferred Stock (par value $0.0001, stated value $1,000 per share).
- Warrants to acquire an aggregate of 1,999,544 shares of Class A Common Stock.
- Conversion/Exercise Terms:
- Preferred Stock conversion price: $7.7644 per share (immediately convertible).
- Warrant exercise price: $7.7644 per share.
- Warrants exercisable starting six months and one day after issuance; expire three years after the initial exercisability date.
- Debt Reduction:
- $10.7 million in outstanding principal debt to Partner Colorado Credit Union (PCCU) was cancelled in exchange for preferred stock and warrants.
- $687,500 in convertible promissory notes issued in August and September 2025 were exchanged for preferred stock and warrants.
- Outstanding Convertible Debt: As of the filing date, the Company has no outstanding convertible debt.
- Forward Purchase Agreement (FPA) Termination: Agreements with Verdun Investments, Vellar Opportunity Fund, and Midtown East Management were terminated in exchange for preferred stock and warrants.
Material Changes Versus Prior Period
- Stockholders' Equity: The Company previously received notice from Nasdaq on April 7, 2025, of non-compliance due to stockholders' equity falling below the $2.5 million minimum requirement (Rule 5550(b)(1)). The Company believes the September 30 transactions have restored equity above this threshold.
- Capital Structure: Significant dilution occurred through the issuance of Series B Preferred Stock and warrants. Additionally, the Company amended its Common Stock Purchase Agreement (CSPA) with CREO Investments LLC to apply 25% of future net cash proceeds from that agreement toward the redemption of the newly issued Series B Preferred Stock.
- Liabilities: The Company eliminated approximately $11.4 million in debt obligations (PCCU loans and convertible notes) through equity exchanges.
Guidance, Outlook, Risks, and Contingencies
- Registration Rights: The Company agreed to file a Form S-1 registration statement by October 29, 2025, to register the underlying common stock for resale. Management noted that an ongoing government shutdown may delay the effectiveness of this registration.
- Nasdaq Compliance: The Company anticipates its Form 10-Q for the period ended September 30, 2025, will reflect compliance with the $2.5 million equity requirement and expects to maintain this level through December 31, 2025. Awaiting formal confirmation from Nasdaq.
- Stockholder Approval: Issuance of securities to certain management and board members is subject to stockholder approval under Nasdaq Listing Rule 5635(c).
- Risks: Forward-looking statements highlight risks related to cannabis industry regulation, capital market volatility, legal proceedings, and the potential impact of government shutdowns on regulatory filings.
Investor Verification Checklist
- Verify the Company's receipt of formal confirmation from Nasdaq regarding compliance with Rule 5550(b)(1).
- Monitor the filing and effectiveness of the Form S-1 registration statement, noting potential delays due to government shutdowns.
- Review the upcoming Form 10-Q for the period ended September 30, 2025, to confirm the reported stockholders' equity exceeds $2.5 million.
- Track the status of stockholder approval required for the issuance of securities to management and board members.
- Assess the impact of the CSPA amendment requiring 25% of future proceeds to be used for redeeming Series B Preferred Stock.